In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by double bracketing. This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1 and 18 have been amended.

Claims 2-17 and 19 have been canceled.

New claims 20-41 have been added.

1. (Currently amended) A method for targeting a pharmaceutical agent to a noncentral nervous system tissue to treat a noncentral nervous system condition comprising:

administering to a subject in need of such treatment a covalent conjugate of [[*cis*-docosahexanoic]] *cis*-docosahexaenoic acid and a pharmaceutical agent effective for treating said condition, wherein the pharmaceutical agent is calcitriol, 22-oxacalcitriol, fluocalcitriol, calcipotriol, calcipotriene, calcifediol, secalciferol, dihydrotachysterol, 20-epi-1,25 dihydroxyvitamin D3, 1 alpha-hydroxyvitamin D2, or alfacalcidol.

2 - 17. (Canceled)

18. (Currently amended) A pharmaceutical preparation comprising:

a covalent conjugate of [[*cis*-docosahexanoic]] *cis*-docosahexaenoic acid and a noncentral nervous system active agent, and

a pharmaceutically acceptable carrier, wherein the noncentral nervous system active agent is calcitriol, 22-oxacalcitriol, fluocalcitriol, calcipotriol, calcipotriene, calcifediol, secalciferol, dihydrotachysterol, 20-epi-1,25 dihydroxyvitamin D3, 1 alpha-hydroxyvitamin D2, or alfacalcidol.

19. (Canceled)

20. (New) The method of claim 1, wherein the pharmaceutical agent is calcitriol.

21. (New) The method of claim 1, wherein the pharmaceutical agent is 22-oxacalcitriol.

22. (New) The method of claim 1, wherein the pharmaceutical agent is fluocalcitriol.

23. (New) The method of claim 1, wherein the pharmaceutical agent is calcipotriol.

24. (New) The method of claim 1, wherein the pharmaceutical agent is calcipotriene.

25. (New) The method of claim 1, wherein the pharmaceutical agent is calcifediol.

26. (New) The method of claim 1, wherein the pharmaceutical agent is secalciferol.

27. (New) The method of claim 1, wherein the pharmaceutical agent is dihydrotachysterol.

28. (New) The method of claim 1, wherein the pharmaceutical agent is 20-epi-1,25 dihydroxyvitamin D3.

29. (New) The method of claim 1, wherein the pharmaceutical agent is 1 alpha-hydroxyvitamin D2.

30. (New) The method of claim 1, wherein the pharmaceutical agent is alfacalcidol.

31. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is calcitriol.

32. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is 22-oxacalcitriol.

33. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is fluocalcitriol.

34. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is calcipotriol.

35. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is calcipotriene.

36. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is calcifediol.

37. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is secalciferol.

38. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is dihydrotachysterol.

39. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is 20-epi-1,25 dihydroxyvitamin D3.

40. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is 1 alpha-hydroxyvitamin D2.

41. (New) The pharmaceutical preparation of claim 18, wherein the noncentral nervous system active agent is alfacalcidol.